1. Targeting Siglec–Sialylated MUC1 Immune Axis in Cancer
    Ramya Ayyalasomayajula et al, 2024, Cancers CrossRef
  2. The Role of MUC1 in Renal Cell Carcinoma
    Martina Milella et al, 2024, Biomolecules CrossRef
  3. A Case of Solitary Pancreatic Metastasis from Gallbladder Cancer
    Shinya Kosuge et al, 2023, The Japanese Journal of Gastroenterological Surgery CrossRef
  4. Immunoengineering can overcome the glycocalyx armour of cancer cells
    Sangwoo Park et al, 2024, Nature Materials CrossRef
  5. MUC1 promotes cancer stemness and predicts poor prognosis in osteosarcoma
    Jian Liu et al, 2023, Pathology - Research and Practice CrossRef
  6. Aptamers as Potential Therapeutic Tools for Ovarian Cancer: Advancements and Challenges
    Wojciech Szymanowski et al, 2023, Cancers CrossRef
  7. Intrahepatic cholangiocarcinoma biomarkers: Towards early detection and personalized pharmacological treatments
    Maurizio Capuozzo et al, 2024, Molecular and Cellular Probes CrossRef
  8. Tn antigen interactions of macrophage galactose-type lectin (MGL) in immune function and disease
    Berna Tumoglu et al, 2023, Glycobiology CrossRef
  9. Overcoming effector T cell exhaustion in ovarian cancer ascites with a novel adenovirus encoding for a MUC1 bispecific antibody engager and IL-2 cytokine
    Saru Basnet et al, 2024, Molecular Therapy CrossRef
  10. Integrative big transcriptomics data analysis implicates crucial role of MUC13 in pancreatic cancer
    Anupam Dhasmana et al, 2023, Computational and Structural Biotechnology Journal CrossRef
  11. A case of ductal carcinoma in situ (DCIS) with markedly elevated CA15-3 levels requiring 2 years of diagnosis
    Mutsumi Fujimoto et al, 2023, Surgical Case Reports CrossRef
  12. Clinical significance of KL-6 in immune-checkpoint inhibitor treatment for non-small cell lung cancer
    Kenji Nakahama et al, 2023, Cancer Chemotherapy and Pharmacology CrossRef
  13. Adoptive Cell Therapy in Hepatocellular Carcinoma: A Review of Clinical Trials
    Muhammet Ozer et al, 2023, Cancers CrossRef
  14. Tandem CAR-T cells targeting MUC1 and PSCA combined with anti-PD-1 antibody exhibit potent preclinical activity against non-small cell lung cancer
    Aying Wang et al, 2023, Cellular Immunology CrossRef